Prelude Therapeutics (PRLD) Stock Statistics & Valuation Metrics

Prelude Therapeutics has a market cap or net worth of $192.16M. The enterprise value is $152.50M.

Prelude Therapeutics has 48,274,113 shares outstanding. The number of shares has decreased by -2.65% in one year.

Prelude Therapeutics’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -114.83%.

The current PE Ratio of Prelude Therapeutics is ―. Prelude Therapeutics’s PEG ratio is 0.10.

In the last 12 months, Prelude Therapeutics had revenue of 12.14M and earned -99.50M in profits. Earnings per share was -1.29.

In the last 12 months, operating cash flow was -56.30M and capital expenditures -67.00K, giving a free cash flow of -56.37M billion.

Prelude Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Prelude Therapeutics upcoming earnings date is May 12, 2026, Before Open (Confirmed).

Prelude Therapeutics as a current ratio of 1.99, with Debt / Equity ratio of 25.92%

In the past 12 months, Prelude Therapeutics has paid 0.00 in taxes.

Prelude Therapeutics EV to EBITDA ratio is -1.40, with an EV/FCF ratio of -2.56.

Prelude Therapeutics has $103.21M in cash and marketable securities with $17.79M in debt, giving a net cash position of $85.42M billion.

Gross margin is 93.06%, with operating margin of -861.33%, and net profit margin of -819.59%.

The average price target for Prelude Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy